Pasithea Therapeutics Warrants
KTTAW
5 hedge funds and large institutions have $5.52K invested in Pasithea Therapeutics Warrants in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
19% less capital invested
Capital invested by funds: $6.83K → $5.52K (-$1.31K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
+$183 |
| 2 |
TSS
Two Sigma Securities
New York
|
+$1 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KC
1
Kepos Capital
New York
| $4K | – | – | – |
|
|
AC
2
Armistice Capital
New York
| $565 | – | – | – |
|
|
TSS
3
Two Sigma Securities
New York
| $556 | +$1 | +65 | +0.1% |
|
|
MG
4
Marex Group
London,
| $250 | – | – | – |
|
|
5
Osaic Holdings
Scottsdale,
Arizona
| $150 | +$183 | +15,000 | New |
|
KTTAW Hedge Fund Activity: Q1 2026 in Review
5 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q1 2026, worth a combined $5.52K — down 19% from $6.83K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new KTTAW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Osaic Holdings, opening a new position worth an estimated $183.
- 5 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q1 2026, up from 4 in Q4 2025.
- Funds reported $5.52K of Pasithea Therapeutics Warrants stock for Q1 2026, down 19% quarter-over-quarter.
- 1 fund opened new Pasithea Therapeutics Warrants positions in Q1 2026 and 0 closed out, a net change of +1 holder.
- The largest Pasithea Therapeutics Warrants buyer in Q1 2026 was Osaic Holdings, an estimated $183 added.
Based on aggregated 13F filings for Q1 2026.